Skip to main content
Erschienen in: Familial Cancer 2/2012

01.06.2012 | Original Article

Management of duodenal adenomatosis in FAP: single centre experience

verfasst von: Musa Drini, Anthony Speer, Christopher Dow, Neil Collier, Prithi Bhathal, Finlay A. Macrae

Erschienen in: Familial Cancer | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Duodenal and ampullary carcinoma in familial adenomatosis (FAP) is the third leading cause of FAP related deaths. Management of this condition is a challenging. The aim of this study was to evaluate the role of multiple targeted endoscopic biopsies and macroscopic appearance as the major determinants for surgical intervention. A secondary aim was to assess histological heterogeneity through comparing endoscopic biopsies and describe the clinical outcomes of our cohort after intervention. We reviewed our FAP surveillance database of 67 patients, between January 1999—June 2011 undergoing upper GI surveillance and where indicated, subsequent surgical intervention. Among 67 patients, 11 underwent surgical resection. Pancreas-preserving duodenectomy was performed in four patients (five procedures), and Whipple’s operation in seven patients. The average size of polyps was 43 mm (range 17–65 mm), and the average number of targeted endoscopic biopsies per lesion was 7.5 (range 5–10). Two cases of high-grade (severe) dysplasia were diagnosed on endoscopic biopsies each understaged compared with the subsequent surgical specimen. All carcinomas identified have been resectable with no evidence of local spread or distant metastasis. There was one postoperative death, but no cancer related deaths. We identified both cancers at an early stage and there were no missed or late diagnoses. There have been no recurrences of carcinoma in a more than 7 years follow-up. Due to the heterogeneous nature of these lesions, comprehensive macroscopic assessment should be complemented with multiple targeted biopsies to improve the chance of early detection of advanced lesions.
Literatur
1.
Zurück zum Zitat Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253(5020):661–665PubMedCrossRef Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253(5020):661–665PubMedCrossRef
2.
Zurück zum Zitat Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J (1994) Familial adenomatosis polyposis (FAP): frequency, penetrance and mutation rate. Hum Mutat 3(2):121–125PubMedCrossRef Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J (1994) Familial adenomatosis polyposis (FAP): frequency, penetrance and mutation rate. Hum Mutat 3(2):121–125PubMedCrossRef
3.
Zurück zum Zitat Kurtz RC, Sternberg SS, Miller HH, Decosse JJ (1987) Upper gastrointestinal neoplasia in familial polyposis. Dig Dis Sci 32(5):459–465PubMedCrossRef Kurtz RC, Sternberg SS, Miller HH, Decosse JJ (1987) Upper gastrointestinal neoplasia in familial polyposis. Dig Dis Sci 32(5):459–465PubMedCrossRef
4.
Zurück zum Zitat Buchi KN, Becker JM, Burt RW (1988) Duodenal polyposis and malignancy in a case of familial polyposis coli. Am J Gastroenterol 83(9):985–987PubMed Buchi KN, Becker JM, Burt RW (1988) Duodenal polyposis and malignancy in a case of familial polyposis coli. Am J Gastroenterol 83(9):985–987PubMed
5.
Zurück zum Zitat Alexander JR, Andrews JM, Buchi KN, Lee RG, Becker JM, Burt RW (1989) High prevalence of adenomatous polyps of the duodenal papilla in familial adenomatous polyposis. Dig Dis Sci 34(2):167–170PubMedCrossRef Alexander JR, Andrews JM, Buchi KN, Lee RG, Becker JM, Burt RW (1989) High prevalence of adenomatous polyps of the duodenal papilla in familial adenomatous polyposis. Dig Dis Sci 34(2):167–170PubMedCrossRef
6.
Zurück zum Zitat Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2(8666):783–785PubMedCrossRef Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2(8666):783–785PubMedCrossRef
7.
Zurück zum Zitat n Cappel WH, Järvinen HJ, Björk J, Berk T, Griffioen G, Vasen HF (2003) Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. Br J Surg 90(6):705–710CrossRef n Cappel WH, Järvinen HJ, Björk J, Berk T, Griffioen G, Vasen HF (2003) Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. Br J Surg 90(6):705–710CrossRef
8.
Zurück zum Zitat Penna C, Bataille N, Balladur P, Tiret E, Parc R (1998) Surgical treatment of severe duodenal polyposis in familial adenomatous polyposis. Br J Surg 85(5):665–668PubMedCrossRef Penna C, Bataille N, Balladur P, Tiret E, Parc R (1998) Surgical treatment of severe duodenal polyposis in familial adenomatous polyposis. Br J Surg 85(5):665–668PubMedCrossRef
9.
Zurück zum Zitat Groves CJ, Saunders BP, Spigelman AD, Phillips RK (2002) Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 50(5):636–641PubMedCrossRef Groves CJ, Saunders BP, Spigelman AD, Phillips RK (2002) Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 50(5):636–641PubMedCrossRef
10.
Zurück zum Zitat Bulow S, Björk J, Christensen IJ, Fausa O, Järvinen H, Moesgaard F, Vasen HF, DAF Study Group (2004) Duodenal adenomatosis in familial adenomatous polyposis. Gut 53(3):381–386PubMedCrossRef Bulow S, Björk J, Christensen IJ, Fausa O, Järvinen H, Moesgaard F, Vasen HF, DAF Study Group (2004) Duodenal adenomatosis in familial adenomatous polyposis. Gut 53(3):381–386PubMedCrossRef
11.
Zurück zum Zitat Parc Y, Mabrut JY, Shields C (2011) Surgical management of the duodenal manifestations of the familial adenomatous polyposis. Br J Surg 98(4):480–484PubMedCrossRef Parc Y, Mabrut JY, Shields C (2011) Surgical management of the duodenal manifestations of the familial adenomatous polyposis. Br J Surg 98(4):480–484PubMedCrossRef
12.
Zurück zum Zitat Seifert E, Schulte F, Stolte M (1992) Adenoma and carcinoma of the duodenum and papilla of vater: a clinicopathologic study. Am J Gastroenterol 87(1):37–42PubMed Seifert E, Schulte F, Stolte M (1992) Adenoma and carcinoma of the duodenum and papilla of vater: a clinicopathologic study. Am J Gastroenterol 87(1):37–42PubMed
13.
Zurück zum Zitat Perzin KH, Bridge MF (1981) Adenomas of the small intestine: a clinicopathologic review of 57 cases and a study of their relationship to carcinoma. Cancer 48(3):799–819PubMedCrossRef Perzin KH, Bridge MF (1981) Adenomas of the small intestine: a clinicopathologic review of 57 cases and a study of their relationship to carcinoma. Cancer 48(3):799–819PubMedCrossRef
14.
Zurück zum Zitat Yamaguchi K, Enjoji M (1987) Carcinoma of the ampulla of vater. A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer 59(3):506–515PubMedCrossRef Yamaguchi K, Enjoji M (1987) Carcinoma of the ampulla of vater. A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer 59(3):506–515PubMedCrossRef
15.
Zurück zum Zitat Saurin JC, Gutknecht C, Napoleon B, Chavaillon A, Ecochard R, Scoazec JY, Ponchon T, Chayvialle JA (2004) Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 22(3):493–498PubMedCrossRef Saurin JC, Gutknecht C, Napoleon B, Chavaillon A, Ecochard R, Scoazec JY, Ponchon T, Chayvialle JA (2004) Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 22(3):493–498PubMedCrossRef
16.
Zurück zum Zitat Cheng C, Sherman S, Fogel EL, McHenry L, Watkins JL, Fukushima T, Howard TJ, Lazzell-Pannell L, Lehman GA (2004) Endoscopic snare papillectomy for tumors of the duodenal papillae. Gastrointest Endosc 60(5):757–764PubMedCrossRef Cheng C, Sherman S, Fogel EL, McHenry L, Watkins JL, Fukushima T, Howard TJ, Lazzell-Pannell L, Lehman GA (2004) Endoscopic snare papillectomy for tumors of the duodenal papillae. Gastrointest Endosc 60(5):757–764PubMedCrossRef
17.
Zurück zum Zitat Wong RF, DiSario JA (2006) Endoscopic Ampullectomy: management of periampullary/duodenal adenomas in familial adenomatous polyposis. Tech Gastrointest Endosc 8(3):103–109CrossRef Wong RF, DiSario JA (2006) Endoscopic Ampullectomy: management of periampullary/duodenal adenomas in familial adenomatous polyposis. Tech Gastrointest Endosc 8(3):103–109CrossRef
18.
Zurück zum Zitat Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications and outcomes. Ann Surg 226(3):248–260PubMedCrossRef Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications and outcomes. Ann Surg 226(3):248–260PubMedCrossRef
19.
Zurück zum Zitat Causeret S, François Y, Griot JB, Flourie B, Gilly FN, Vignal J (1998) Prophylactic pancreaticoduodenectomy for premalignant duodenal polyposis in familial adenomatous polyposis. Int J Colorectal Dis 13(1):39–42PubMedCrossRef Causeret S, François Y, Griot JB, Flourie B, Gilly FN, Vignal J (1998) Prophylactic pancreaticoduodenectomy for premalignant duodenal polyposis in familial adenomatous polyposis. Int J Colorectal Dis 13(1):39–42PubMedCrossRef
20.
Zurück zum Zitat Mackey R, Walsh RM, Chung R, Brown N, Smith A, Church J, Burke C (2005) Pancreas-sparing duodenectomy is effective management for familial adenomatous polyposis. J Gastrointest Surg 9(8):1088–1093PubMedCrossRef Mackey R, Walsh RM, Chung R, Brown N, Smith A, Church J, Burke C (2005) Pancreas-sparing duodenectomy is effective management for familial adenomatous polyposis. J Gastrointest Surg 9(8):1088–1093PubMedCrossRef
21.
Zurück zum Zitat Gallagher MC, Shankar A, Groves CJ, Russell RC, Phillips RK (2004) Pylorus-preserving pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous polyposis. Br J Surg 91(9):1157–1164PubMedCrossRef Gallagher MC, Shankar A, Groves CJ, Russell RC, Phillips RK (2004) Pylorus-preserving pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous polyposis. Br J Surg 91(9):1157–1164PubMedCrossRef
Metadaten
Titel
Management of duodenal adenomatosis in FAP: single centre experience
verfasst von
Musa Drini
Anthony Speer
Christopher Dow
Neil Collier
Prithi Bhathal
Finlay A. Macrae
Publikationsdatum
01.06.2012
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2012
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9496-0

Weitere Artikel der Ausgabe 2/2012

Familial Cancer 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.